Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled, crossover study.
Identifieur interne : 003A68 ( Main/Exploration ); précédent : 003A67; suivant : 003A69Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled, crossover study.
Auteurs : H. Shinotoh [Canada] ; F J Vingerhoets ; C S Lee ; R J Uitti ; M. Schulzer ; D B Calne ; J. TsuiSource :
- Neurology [ 0028-3878 ] ; 1997.
English descriptors
- KwdEn :
- Adult, Anticonvulsants (administration & dosage), Anticonvulsants (therapeutic use), Antiparkinson Agents (therapeutic use), Carbidopa (therapeutic use), Cross-Over Studies, Dose-Response Relationship, Drug, Double-Blind Method, Drug Combinations, Female, Humans, Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (drug therapy), Placebos, Treatment Outcome, Triazines (administration & dosage), Triazines (therapeutic use).
- MESH :
- chemical , administration & dosage : Anticonvulsants, Triazines.
- chemical , therapeutic use : Anticonvulsants, Antiparkinson Agents, Carbidopa, Levodopa, Triazines.
- drug therapy : Parkinson Disease.
- Adult, Cross-Over Studies, Dose-Response Relationship, Drug, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Placebos, Treatment Outcome.
Abstract
Increased glutamatergic transmission in the basal ganglia is implicated in the pathophysiology of idiopathic parkinsonism (IP). We investigated the effects of lamotrigine (LTG), a glutamate-release inhibitor, in the symptomatic treatment of IP in two double-blind, placebo-controlled studies. Single doses of L-dopa/carbidopa (equal to 50% of the usual morning dose) were administered together with either LTG (100, 200, or 400 mg) or two random placebo doses in 14 patients with IP. The patients were assessed using the Modified Columbia Rating Scale (MCRS) and the Purdue Pegboard Test (PPBT) at multiple intervals over 8 hours. There were no significant differences between the placebo doses and the three doses of LTG on the MCRS and PPBT scores. In a 3-month study, 12 patients took LTG titrated up to 400 mg or placebo with their antiparkinsonian medication for 3 months and were then crossed over. Nine of 12 patients did not complete the study because of dyskinesia (n = 2), hallucinations (n = 3), and deterioration of parkinsonian symptoms (n = 4) on LTG. There was no significant difference between placebo and LTG on the MCRS and PPBT in the three patients who completed the study. The results failed to demonstrate any symptomatically beneficial effects of LTG in IP.
PubMed: 9153458
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001828
- to stream PubMed, to step Curation: 001828
- to stream PubMed, to step Checkpoint: 001828
- to stream Ncbi, to step Merge: 002585
- to stream Ncbi, to step Curation: 002585
- to stream Ncbi, to step Checkpoint: 002585
- to stream Main, to step Merge: 004108
- to stream Main, to step Curation: 003A68
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled, crossover study.</title><author><name sortKey="Shinotoh, H" sort="Shinotoh, H" uniqKey="Shinotoh H" first="H" last="Shinotoh">H. Shinotoh</name><affiliation wicri:level="1"><nlm:affiliation>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver</wicri:regionArea><wicri:noRegion>Vancouver</wicri:noRegion></affiliation></author><author><name sortKey="Vingerhoets, F J" sort="Vingerhoets, F J" uniqKey="Vingerhoets F" first="F J" last="Vingerhoets">F J Vingerhoets</name></author><author><name sortKey="Lee, C S" sort="Lee, C S" uniqKey="Lee C" first="C S" last="Lee">C S Lee</name></author><author><name sortKey="Uitti, R J" sort="Uitti, R J" uniqKey="Uitti R" first="R J" last="Uitti">R J Uitti</name></author><author><name sortKey="Schulzer, M" sort="Schulzer, M" uniqKey="Schulzer M" first="M" last="Schulzer">M. Schulzer</name></author><author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D B" last="Calne">D B Calne</name></author><author><name sortKey="Tsui, J" sort="Tsui, J" uniqKey="Tsui J" first="J" last="Tsui">J. Tsui</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1997">1997</date><idno type="RBID">pubmed:9153458</idno><idno type="pmid">9153458</idno><idno type="wicri:Area/PubMed/Corpus">001828</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001828</idno><idno type="wicri:Area/PubMed/Curation">001828</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001828</idno><idno type="wicri:Area/PubMed/Checkpoint">001828</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001828</idno><idno type="wicri:Area/Ncbi/Merge">002585</idno><idno type="wicri:Area/Ncbi/Curation">002585</idno><idno type="wicri:Area/Ncbi/Checkpoint">002585</idno><idno type="wicri:doubleKey">0028-3878:1997:Shinotoh H:lamotrigine:trial:in</idno><idno type="wicri:Area/Main/Merge">004108</idno><idno type="wicri:Area/Main/Curation">003A68</idno><idno type="wicri:Area/Main/Exploration">003A68</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled, crossover study.</title><author><name sortKey="Shinotoh, H" sort="Shinotoh, H" uniqKey="Shinotoh H" first="H" last="Shinotoh">H. Shinotoh</name><affiliation wicri:level="1"><nlm:affiliation>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver</wicri:regionArea><wicri:noRegion>Vancouver</wicri:noRegion></affiliation></author><author><name sortKey="Vingerhoets, F J" sort="Vingerhoets, F J" uniqKey="Vingerhoets F" first="F J" last="Vingerhoets">F J Vingerhoets</name></author><author><name sortKey="Lee, C S" sort="Lee, C S" uniqKey="Lee C" first="C S" last="Lee">C S Lee</name></author><author><name sortKey="Uitti, R J" sort="Uitti, R J" uniqKey="Uitti R" first="R J" last="Uitti">R J Uitti</name></author><author><name sortKey="Schulzer, M" sort="Schulzer, M" uniqKey="Schulzer M" first="M" last="Schulzer">M. Schulzer</name></author><author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D B" last="Calne">D B Calne</name></author><author><name sortKey="Tsui, J" sort="Tsui, J" uniqKey="Tsui J" first="J" last="Tsui">J. Tsui</name></author></analytic><series><title level="j">Neurology</title><idno type="ISSN">0028-3878</idno><imprint><date when="1997" type="published">1997</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Anticonvulsants (administration & dosage)</term><term>Anticonvulsants (therapeutic use)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Carbidopa (therapeutic use)</term><term>Cross-Over Studies</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Combinations</term><term>Female</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Placebos</term><term>Treatment Outcome</term><term>Triazines (administration & dosage)</term><term>Triazines (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anticonvulsants</term><term>Triazines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticonvulsants</term><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Levodopa</term><term>Triazines</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Cross-Over Studies</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Combinations</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Placebos</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Increased glutamatergic transmission in the basal ganglia is implicated in the pathophysiology of idiopathic parkinsonism (IP). We investigated the effects of lamotrigine (LTG), a glutamate-release inhibitor, in the symptomatic treatment of IP in two double-blind, placebo-controlled studies. Single doses of L-dopa/carbidopa (equal to 50% of the usual morning dose) were administered together with either LTG (100, 200, or 400 mg) or two random placebo doses in 14 patients with IP. The patients were assessed using the Modified Columbia Rating Scale (MCRS) and the Purdue Pegboard Test (PPBT) at multiple intervals over 8 hours. There were no significant differences between the placebo doses and the three doses of LTG on the MCRS and PPBT scores. In a 3-month study, 12 patients took LTG titrated up to 400 mg or placebo with their antiparkinsonian medication for 3 months and were then crossed over. Nine of 12 patients did not complete the study because of dyskinesia (n = 2), hallucinations (n = 3), and deterioration of parkinsonian symptoms (n = 4) on LTG. There was no significant difference between placebo and LTG on the MCRS and PPBT in the three patients who completed the study. The results failed to demonstrate any symptomatically beneficial effects of LTG in IP.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D B" last="Calne">D B Calne</name><name sortKey="Lee, C S" sort="Lee, C S" uniqKey="Lee C" first="C S" last="Lee">C S Lee</name><name sortKey="Schulzer, M" sort="Schulzer, M" uniqKey="Schulzer M" first="M" last="Schulzer">M. Schulzer</name><name sortKey="Tsui, J" sort="Tsui, J" uniqKey="Tsui J" first="J" last="Tsui">J. Tsui</name><name sortKey="Uitti, R J" sort="Uitti, R J" uniqKey="Uitti R" first="R J" last="Uitti">R J Uitti</name><name sortKey="Vingerhoets, F J" sort="Vingerhoets, F J" uniqKey="Vingerhoets F" first="F J" last="Vingerhoets">F J Vingerhoets</name></noCountry><country name="Canada"><noRegion><name sortKey="Shinotoh, H" sort="Shinotoh, H" uniqKey="Shinotoh H" first="H" last="Shinotoh">H. Shinotoh</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A68 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003A68 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:9153458
|texte= Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled, crossover study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:9153458" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |